Dividend and Financial Performance - The company plans to distribute a cash dividend of 0.22 RMB per 10 shares (including tax) to all shareholders[4]. - The company's operating revenue for 2023 was ¥974,512,217.68, representing a 3.30% increase compared to ¥943,396,998.69 in 2022[24]. - Net profit attributable to shareholders for 2023 was ¥119,885,372.42, a 9.55% increase from ¥109,437,321.14 in 2022[24]. - Basic earnings per share for 2023 were ¥0.2020, reflecting a 9.54% increase from ¥0.1844 in 2022[24]. - The weighted average return on equity for 2023 was 7.46%, slightly up from 7.42% in 2022[24]. - The total assets at the end of 2023 reached ¥2,742,011,238.13, an 18.80% increase from ¥2,308,113,622.60 at the end of 2022[24]. - The company achieved operating revenue of ¥974,512,217.68, a year-on-year increase of 3.30%, and a total profit of ¥144,492,588.73, up 9.76% from the previous year[73]. - The company reported a gross margin of 45%, indicating strong operational efficiency[67]. - The total assets of the company increased by 12% to 2 billion RMB, reflecting solid financial health[67]. Revenue Growth and Market Expansion - The company reported a significant increase in revenue, with a year-on-year growth of 15% in the latest fiscal year[19]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the fiscal year, representing a 20% year-over-year growth[67]. - User data showed a 15% increase in active users, reaching 3 million by the end of the year[67]. - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 25%[67]. - New product launches are expected to contribute an additional 300 million RMB in revenue, with a focus on innovative healthcare solutions[67]. - Market expansion plans include entering three new international markets, aiming for a 10% market share within the first year[67]. - The company is actively expanding into the medical, pharmaceutical, aesthetic, and nutritional health food sectors, leveraging its listing platform and brand advantages for multi-dimensional marketing[70]. Production Capacity and Product Development - The company is expanding its production capacity, aiming to increase gelatin production from 3,500 tons to 7,000 tons annually[19]. - The company aims to develop high-value-added collagen products to meet market demand and maintain its leading position in the natural collagen industry[34]. - The company is focusing on the development of ultra-low endotoxin gelatin for regenerative medicine applications, targeting medical devices and pharmaceutical products[37]. - The company has an annual production capacity of 13,500 tons for gelatin and 39 billion capsules, with plans to expand to nearly 70 billion capsules after the completion of the new production project[49]. - The company is actively expanding its production capabilities, with plans to achieve an annual output of 300 billion capsules in the near future, positioning itself as a leading manufacturer in the industry[60]. - The company is focusing on the development of high-end markets, with its blood plasma gelatin included in the national guidelines for upgraded and innovative consumer products, enhancing its market presence[77]. Research and Development - The company is investing heavily in R&D, allocating 10% of its revenue to develop new technologies and improve existing products[67]. - The company has obtained a total of 50 patents, including 28 Chinese invention patents and 1 US invention patent, with 6 new patents granted during the reporting period[65]. - The company has published a total of 45 papers, with 2 new papers published during the reporting period[65]. - The company is focusing on technological innovation and has accelerated the development of high-value collagen projects, including applications in low-fat cream technology and hair care[85]. - The company has established a collaborative research project with Jiangnan University to explore collagen protein applications in the textile industry, which has received funding support[86]. - The company is developing a low-endotoxin gelatin preparation process aimed at enhancing product value and achieving specific technical indicators[99]. Quality Management and Compliance - The company is committed to maintaining compliance with international quality standards, including FDA and ISO certifications[19]. - The company has established a comprehensive quality management system, certified by multiple international standards, ensuring product safety and quality stability[62]. - The company has achieved various quality management certifications, including NSF-GMP and FSSC22000, enhancing its product quality assurance[85]. - The company emphasizes a centralized procurement model to ensure quality control from the sourcing of raw materials to production[56]. Strategic Acquisitions and Partnerships - The company is considering strategic acquisitions to bolster its market position and enhance its product offerings[19]. - The company has established partnerships with various research institutions to advance its technological capabilities[19]. - The company has established stable partnerships with major pharmaceutical companies, ensuring a solid foundation for future business growth[78]. - The company aims to capture more market share in both B2B and B2C sectors due to stricter regulations and accelerated industry consolidation[47]. Financial Management and Investments - The company successfully issued convertible bonds, raising ¥455 million to support business expansion and enhance its health industry layout[75]. - The total investment amount for the reporting period was CNY 195,161,401.38, representing a 25.18% increase compared to the previous year's investment of CNY 155,905,672.96[114]. - The company has committed a total investment of RMB 86.23 million for various projects, with RMB 47.59 million cumulatively invested by the end of the reporting period[126]. - The company has not engaged in any securities or derivative investments during the reporting period[118][119]. - The company has reported a net financial income of RMB 5.54 million from investment returns and bank interest after deducting fees as of December 31, 2023[123]. Governance and Management - The company held 3 shareholder meetings during the reporting period, all convened by the board of directors and presided over by the chairman[160]. - The board of directors consists of 7 members, including 3 independent directors, and has established various committees to ensure compliance with regulations[162]. - The company has established a performance evaluation and incentive system for its executives, ensuring transparency and compliance with legal standards[165]. - The company maintains independent operations from its controlling shareholder, with no instances of fund occupation or guarantees provided to the controlling shareholder[161][168]. - The company has a complete and independent asset structure, with all assets under the control of the listed company[168]. Market Trends and Consumer Insights - The global retail market for nutritional health products reached $182.67 billion in 2023, with an expected CAGR of 5.7% over the next five years, projected to reach $241.1 billion by 2028[38]. - In 2023, the per capita healthcare expenditure in China was ¥2,460, accounting for 9.2% of total consumer spending, showing a year-on-year increase[39]. - The domestic beauty market size was ¥390.3 billion in 2021, with a CAGR of 11.51% from 2007 to 2021, expected to reach ¥577.9 billion by 2026[40]. - The anti-aging skincare market in China grew from ¥35.6 billion in 2016 to ¥82 billion in 2021, with a CAGR of 18.1%, projected to reach ¥153.2 billion by 2026[40]. Challenges and Risks - The company has outlined potential risks in its future operations and has strategies in place to mitigate these risks[4]. - The company is facing risks related to management as it scales operations, necessitating improved operational capabilities and management systems[150]. - The company is addressing intensified market competition by focusing on product innovation and customized technical services to enhance core competitiveness[151].

包头东宝生物技术股份有限公司 董事会关于独立董事独立性情况的专项意见 包头东宝生物技术股份有限公司（以下简称"公司"）董事会根据《上市公 司独立董事管理办法》、《深圳证券交易所创业板股票上市规则》、《深圳证券 交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等要求，对 公司独立董事的独立性情况进行评估并出具如下专项意见： 经核查，公司独立董事高德步先生、任斌先生、额尔敦陶克涛先生均未在公 司担任独立董事以外的任何职务，也未在公司主要股东担任任何职务，与公司及 公司主要股东之间不存在利害关系或其他可能妨碍其进行独立客观判断的关系， 不存在其他影响独立董事独立性的情况。公司独立董事符合《上市公司独立董事 管理办法》、《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公 司规范运作》等法律法规、规范性文件和公司《独立董事工作制度》中关于独立 董事独立性的相关要求。 包头东宝生物技术股份有限公司 董事会 2024 年 4 月 24 日 ...

包头东宝生物技术股份有限公司 2023 年度 募集资金年度存放与使用情况鉴证报告 | 索引 | | 页码 | | --- | --- | --- | | 鉴证报告 | | 1-2 | | 2023 | 年度募集资金年度存放与使用情况的专项报告 | 1-16 | | | | 9/F, Block A, Fu Hua Mansion, | | --- | --- | --- | | 1G | No.8 Chaoyangmen Beidajie, ShineWing Dongcheng District, Beijing, 传真: | +86 (010) 6554 7190 | | 11 | sentified nublic accessuntante (400007 D D China Comments of | 1 | 募集资金年度存放与使用情况鉴证报告 XYZH/2024JNAA1F0012 包头东宝生物技术股份有限公司 包头东宝生物技术股份有限公司全体股东： 我们对后附的包头东宝生物技术股份有限公司(以下简称东宝生物公司)2023 年度 募集资金年度存放与使用情况的专项报告（以下简称募集资金年度存放与使用情 ...

包头东宝生物技术股份有限公司 2023 年度 审计报告 | 索引 | | 页码 | | --- | --- | --- | | 审计报告 | | 1-4 | | 公司财务报表 | | | | — | 合并资产负债表 | 1-2 | | — | 母公司资产负债表 | 3-4 | | — | 合并利润表 | 5 | | — | 母公司利润表 | 6 | | — | 合并现金流量表 | 7 | | — | 母公司现金流量表 | 8 | | — | 合并股东权益变动表 | 9-10 | | — | 母公司股东权益变动表 | 11-12 | | — | 财务报表附注 | 13-97 | 审计报告 XYZH/2024JNAA1B0102 包头东宝生物技术股份有限公司 包头东宝生物技术股份有限公司全体股东： 一、 审计意见 我们审计了包头东宝生物技术股份有限公司（以下简称东宝生物公司）财务报表， 包括 2023 年 12 月 31 日的合并及母公司资产负债表，2023 年度的合并及母公司利润表、 合并及母公司现金流量表、合并及母公司股东权益变动表，以及相关财务报表附注。 我们认为，后附的财务报表在所有重大方面按照企业会计准 ...

| | | 包头东宝生物技术股份有限公司 关于公司及子公司向银行等金融机构 申请综合授信额度的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 包头东宝生物技术股份有限公司（以下简称"公司"）于 2024 年 4 月 22 日召 开第八届董事会第二十次会议、第八届监事会第十九次会议，审议通过了《关于公 司及子公司向银行等金融机构申请综合授信额度的议案》，同意公司及子公司向银 行等金融机构申请合计总额不超过人民币 120,000 万元综合授信额度，在此额度内 由公司及子公司根据实际资金需求进行授信申请。本议案尚需提交公司 2023 年度股 东大会审议批准。现将具体情况公告如下： 一、本次申请综合授信的基本情况： 因生产经营和发展的需要，公司及子公司拟通过抵押、质押、接受控股股东/实 际控制人无偿关联担保等方式向银行等金融机构申请合计总额不超过人民币 120,000 万元综合授信额度(包括不限于流动资金贷款、项目资金贷款、开具银行承兑汇票、 贴现、保理、保函、信用证等业务)。公司、子公司与各授信金融机构之间的综合授 信额度可以相互调整，最终实际授信额度、期限以 ...

Financial Performance - The company's operating revenue for Q1 2024 was ¥241,778,598.22, a decrease of 7.48% compared to ¥261,319,537.08 in the same period last year[5] - Net profit attributable to shareholders was ¥25,961,526.88, down 16.62% from ¥31,137,429.27 year-on-year[5] - Basic earnings per share decreased to ¥0.0437, down 16.76% from ¥0.0525 in the same period last year[5] - Net profit for Q1 2024 was CNY 28,081,767.64, a decline of 19.2% from CNY 34,687,227.19 in Q1 2023[22] - The net profit attributable to shareholders of the parent company was CNY 25,961,526.88, down 16.9% from CNY 31,137,429.27 in the previous year[23] Cash Flow - The net cash flow from operating activities improved to -¥9,408,089.36, a 57.24% increase compared to -¥22,004,098.25 in the previous year[5] - The net cash flow from operating activities for Q1 2024 was -9,408,089.36 CNY, an improvement from -22,004,098.25 CNY in Q1 2023[26] - The company’s cash inflow from operating activities totaled 136,276,694.96 CNY, compared to 124,794,028.45 CNY in Q1 2023, reflecting a year-over-year increase[26] - The total cash outflow from operating activities was 145,684,784.32 CNY, slightly lower than 146,798,126.70 CNY in the same quarter last year[26] - The company reported a financial expense of CNY -1,700,412.18, compared to CNY 198,304.19 in the previous year, indicating improved financial management[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,755,359,790.94, reflecting a slight increase of 0.49% from ¥2,742,011,238.13 at the end of the previous year[5] - Total liabilities as of Q1 2024 were CNY 833,079,077.16, a slight decrease from CNY 848,818,198.38 in the previous year[22] - The total number of common shareholders at the end of the reporting period is 25,755[14] - The total equity attributable to shareholders increased by 1.57% to ¥1,684,029,096.94 from ¥1,658,061,663.67 at the end of the previous year[5] - Total equity increased to CNY 1,922,280,713.78 from CNY 1,893,193,039.75 year-over-year[22] Research and Development - Research and development expenses decreased by 32.00% to ¥4,046,567.55 from ¥5,950,698.74 in the previous year[11] - Research and development expenses for Q1 2024 were CNY 4,046,567.55, down from CNY 5,950,698.74 in Q1 2023[22] Income and Expenses - The company reported a significant increase in other income, which rose by 122.81% to ¥2,868,307.89 compared to ¥1,287,359.67 in the previous year[11] - The company experienced a 681.72% increase in other operating expenses, totaling ¥875,742.61 compared to ¥112,027.07 in the previous year[11] - Total operating costs for Q1 2024 were CNY 209,838,876.06, down 5.0% from CNY 220,984,145.75 in the same period last year[22] Cash and Cash Equivalents - The company's cash and cash equivalents increased to ¥759,897,550.09 from ¥748,691,388.11[17] - Cash and cash equivalents at the end of Q1 2024 stood at 715,787,550.09 CNY, up from 257,633,996.41 CNY at the end of Q1 2023[27] - The net increase in cash and cash equivalents for Q1 2024 was 2,336,158.08 CNY, contrasting with a decrease of 80,823,303.64 CNY in the previous year[26] Shareholder Information - The largest shareholder, Qingdao Guoen Technology Co., Ltd., holds 21.18% of shares, totaling 125,711,022 shares, with 88,000,000 shares pledged[14] - The total number of preferred shareholders is zero, indicating no preferred shares outstanding[16] - The company has no significant changes in the top ten shareholders participating in margin trading[15] Investment Activities - The net cash flow from investing activities was ¥9,150,743.28, an increase of 185.48% from ¥10,705,182.69 in the previous year[13] - Total cash inflow from investment activities was 33,220,361.53 CNY, significantly higher than 15,000.00 CNY in the same period last year[26] Audit Information - The company did not undergo an audit for the Q1 2024 report[28]

| 证券代码：300239 | 证券简称：东宝生物 | 公告编号：2024-025 | | --- | --- | --- | | 债券代码：123214 | 债券简称：东宝转债 | | 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 包头东宝生物技术股份有限公司(以下简称"公司")定于2024年5月14日(星期二) 下午14:00召开2023年度股东大会。现将本次会议有关事项通知如下： 一、召开会议的基本情况 1、会议届次：包头东宝生物技术股份有限公司2023年度股东大会。 2、会议召集人：公司董事会。 3、会议召开的合法、合规性：经公司第八届董事会第二十次会议审议通过，定 于2024年5月14日(星期二)下午14:00召开2023年度股东大会。本次股东大会的召集程 序符合有关法律、行政法规、部门规章、规范性文件、深交所业务规则以及《公司 章程》等有关规定。 4、会议召开日期、时间： 包头东宝生物技术股份有限公司 关于召开 2023 年度股东大会的通知 (1)现场会议时间：2024年5月14日(星期二)下午14:00 (2)网络投票时间：2024年5月14日 ...

招商证券股份有限公司 关于包头东宝生物技术股份有限公司 使用暂时闲置募集资金及自有资金进行现金管理的核查意见 招商证券股份有限公司（以下简称"招商证券"、"保荐机构"）作为包头东宝 生物技术股份有限公司（以下简称"东宝生物"、"公司"）持续督导的保荐机构， 根据《证券发行上市保荐业务管理办法》、《深圳证券交易所创业板股票上市规则》、 《深圳证券交易所上市公司自律监管指引第 2 号—创业板上市公司规范运作》等 相关法律、法规及规范性文件，对东宝生物使用暂时闲置募集资金及自有资金进 行现金管理的事项进行了核查，核查情况如下： 一、使用暂时闲置募集资金及自有资金进行现金管理基本情况 东宝生物于2024年4月22日召开第八届董事会第二十次会议、第八届监事会 第十九次会议，审议通过了《关于使用部分暂时闲置募集资金及自有资金进行现 金管理的议案》，同意公司在确保不影响募集资金投资项目建设、不改变募集资 金使用用途、不影响公司正常生产经营以及确保资金安全的前提下，使用额度不 超过35,000万元(含本数)的部分暂时闲置募集资金和不超过30,000万元(含本数) 自有资金(合计不超过65,000万元，含本数)进行现金管理，期 ...

包头东宝生物技术股份有限公司 独立董事 2023 年度述职报告 (任斌) 各位股东及股东代表： 本人任斌，作为包头东宝生物技术股份有限公司(以下简称"公司")第八届董 事会独立董事，2023 年度，严格按照《上市公司独立董事管理办法》、《深圳 证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等法律、 法规和《公司章程》、公司《独立董事工作制度》等规章制度的有关规定，本着 客观、公正、独立的原则及对全体股东负责的态度，勤勉尽责、独立履职，促进 公司规范运作、健康发展，维护公司、全体股东特别是中小股东的利益。现将本 人 2023 年度工作情况报告如下： 一、独立董事基本情况 任斌，男，1962 年 9 月出生，中国国籍，无永久境外居留权，中国农业大 学农业推广硕士。1985 年 7 月至今，任教于内蒙古农业大学，从事科研、农业 技术推广、实践教学和创新创业教育工作，参与多项农牧业科研项目、国家重点 研发计划项目；2020 年 5 月至今，任公司独立董事、薪酬和考核委员会召集人、 战略委员会委员。 本人作为公司第八届董事会独立董事，未在公司担任独立董事以外的任何职 务，也未在公司主要股东担任任何 ...

包头东宝生物技术股份有限公司内部控制评价报告 2023 年 12 月 31 日 包头东宝生物技术股份有限公司 内部控制评价报告 包头东宝生物技术股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要 求（以下简称"企业内部控制规范体系"），结合包头东宝生物技术股份有限公 司（以下简称"公司"）内部控制制度和评价办法，在内部控制日常监督和专项 监督的基础上，我们对公司截止 2023 年 12 月 31 日（内部控制评价报告基准日） 的内部控制有效性进行了评价。 一、重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其 有效性，并如实披露内部控制评价报告是公司董事会的责任。监事会对董事会建 立和实施内部控制进行监督。经理层负责组织领导企业内部控制的日常运行。公 司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存在任何虚假 记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个 别及连带法律责任。 二、内部控制评价结论 根据公司财务报告内部控制重大缺陷的认定情况，于内部控制评价报告基准 日，不存在财务报告内部控制重大缺陷。董事会认 ...